单中心随机试验的阳性结果与后续多中心随机试验在危重症患者中的一致性:一项系统评价
该系统评价检索PubMed中发表于《新英格兰医学杂志》《美国医学会杂志》或《柳叶刀》、至2016年12月31日的单中心随机对照试验(sRCT),纳入报告成人危重症患者任何干预(药物、技术或策略)使死亡率统计学显著下降的研究,并查找针对同一研究问题的后续多中心随机对照试验(mRCT)。共识别19项sRCT,其中16项有至少一项后续mRCT(共24项试验),3项sRCT的干预尚未在后续mRCT中检验。16项sRCT中仅1项(6%)的死亡率下降被后续mRCT复制,14项(88%)的后续mRCT未显示死亡率差异;1项(6%)关于强化血糖控制的sRCT阳性结果被后续mRCT推翻,后者显示死亡率显著增加。14项被国际指南至少引用一次的sRCT中,6项(43%)在最新版相关指南中已被移除或建议反对。作者结论认为单中心RCT的死亡率下降结果通常不能被多中心RCT复制,应视为产生假设,不应影响指南制定。
要点
- 19项报告成人危重症患者死亡率显著下降的sRCT中,16项有后续mRCT(共24项试验),仅1项(6%)的死亡率下降被mRCT复制。
- 14项(88%)sRCT的后续mRCT未显示死亡率差异;1项(6%)强化血糖控制的sRCT阳性结果被后续mRCT推翻,后者显示死亡率显著增加。
- 14项被国际指南至少引用一次的sRCT中,6项(43%)在最新版相关指南中已被移除或建议反对。
- 3项sRCT的干预尚未在后续mRCT中检验。
- 作者认为sRCT显示的死亡率下降通常不能被mRCT复制,sRCT结果应视为产生假设,不应影响指南制定。
适用人群与场景
- 成人危重症患者,涉及药物、技术或策略干预的sRCT,报告统计学显著的死亡率下降。
研究设计与关键结果
- 系统评价检索PubMed中发表于《新英格兰医学杂志》《美国医学会杂志》或《柳叶刀》、至2016年12月31日的sRCT,纳入报告成人危重症患者任何干预(药物、技术或策略)使死亡率统计学显著下降的研究,并查找针对同一研究问题的后续mRCT。
- 共识别19项sRCT报告成人危重症患者死亡率显著下降;其中16项有至少一项后续mRCT(共24项试验),3项sRCT的干预尚未在后续mRCT中检验。
- 16项sRCT中仅1项(6%)的死亡率下降被后续mRCT复制;14项(88%)的后续mRCT未显示死亡率差异。
- 1项(6%)关于强化血糖控制的sRCT阳性结果被后续mRCT推翻,后者显示死亡率显著增加。
- 14项被国际指南至少引用一次的sRCT中,6项(43%)在最新版相关指南中已被移除或建议反对。
证据类型、等级与局限
- 系统评价,已在PROSPERO国际前瞻性系统评价注册库注册(CRD42023455362)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为sRCT显示的死亡率下降通常不能被mRCT复制,sRCT结果应视为产生假设,不应影响指南制定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: It is unclear how often survival benefits observed in single-center randomized controlled trials (sRCTs) involving critically ill patients are confirmed by subsequent multicenter randomized controlled trials (mRCTs). We aimed to perform a systemic literature review of sRCTs with a statistically significant mortality reduction and to evaluate whether subsequent mRCTs confirmed such reduction.
METHODS: We searched PubMed for sRCTs published in the New England Journal of Medicine, JAMA, or Lancet, from inception until December 31, 2016. We selected studies reporting a statistically significant mortality decrease using any intervention (drug, technique, or strategy) in adult critically ill patients. We then searched for subsequent mRCTs addressing the same research question tested by the sRCT. We compared the concordance of results between sRCTs and mRCTs when any mRCT was available. We registered this systematic review in the PROSPERO International Prospective Register of Systematic Reviews (CRD42023455362).
RESULTS: We identified 19 sRCTs reporting a significant mortality reduction in adult critically ill patients. For 16 sRCTs, we identified at least one subsequent mRCT (24 trials in total), while the interventions from three sRCTs have not yet been addressed in a subsequent mRCT. Only one out of 16 sRCTs (6%) was followed by a mRCT replicating a significant mortality reduction; 14 (88%) were followed by mRCTs with no mortality difference. The positive finding of one sRCT (6%) on intensive glycemic control was contradicted by a subsequent mRCT showing a significant mortality increase. Of the 14 sRCTs referenced at least once in international guidelines, six (43%) have since been either removed or suggested against in the most recent versions of relevant guidelines.
CONCLUSION: Mortality reduction shown by sRCTs is typically not replicated by mRCTs. The findings of sRCTs should be considered hypothesis-generating and should not contribute to guidelines.
参考来源
- Kotani Y, Turi S, Ortalda A, et al. Positive single-center randomized trials and subsequent multicenter randomized trials in critically ill patients: a systematic review. Crit Care. 2023. PMID: 38017475. doi:10.1186/s13054-023-04755-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。